These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of Kolb HC; Barret O; Bhattacharya A; Chen G; Constantinescu C; Huang C; Letavic M; Tamagnan G; Xia CA; Zhang W; Szardenings AK J Nucl Med; 2019 Aug; 60(8):1154-1159. PubMed ID: 30733317 [TBL] [Abstract][Full Text] [Related]
8. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. Bhattacharya A; Lord B; Grigoleit JS; He Y; Fraser I; Campbell SN; Taylor N; Aluisio L; O'Connor JC; Papp M; Chrovian C; Carruthers N; Lovenberg TW; Letavic MA Neuropsychopharmacology; 2018 Dec; 43(13):2586-2596. PubMed ID: 30026598 [TBL] [Abstract][Full Text] [Related]
9. Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Rudolph DA; Alcazar J; Ameriks MK; Anton AB; Ao H; Bonaventure P; Carruthers NI; Chrovian CC; De Angelis M; Lord B; Rech JC; Wang Q; Bhattacharya A; Andres JI; Letavic MA Bioorg Med Chem Lett; 2015 Aug; 25(16):3157-63. PubMed ID: 26099534 [TBL] [Abstract][Full Text] [Related]
10. Koole M; Schmidt ME; Hijzen A; Ravenstijn P; Vandermeulen C; Van Weehaeghe D; Serdons K; Celen S; Bormans G; Ceusters M; Zhang W; Van Nueten L; Kolb H; de Hoon J; Van Laere K J Nucl Med; 2019 May; 60(5):683-690. PubMed ID: 30262518 [TBL] [Abstract][Full Text] [Related]
11. Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain. Chrovian CC; Soyode-Johnson A; Ao H; Bacani GM; Carruthers NI; Lord B; Nguyen L; Rech JC; Wang Q; Bhattacharya A; Letavic MA ACS Chem Neurosci; 2016 Apr; 7(4):490-7. PubMed ID: 26752113 [TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists. Ameriks MK; Ao H; Carruthers NI; Lord B; Ravula S; Rech JC; Savall BM; Wall JL; Wang Q; Bhattacharya A; Letavic MA Bioorg Med Chem Lett; 2016 Jan; 26(2):257-261. PubMed ID: 26707399 [TBL] [Abstract][Full Text] [Related]
13. PET Imaging of the P2X7 Ion Channel with a Novel Tracer [ Berdyyeva T; Xia C; Taylor N; He Y; Chen G; Huang C; Zhang W; Kolb H; Letavic M; Bhattacharya A; Szardenings AK Mol Imaging Biol; 2019 Oct; 21(5):871-878. PubMed ID: 30632003 [TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294 [TBL] [Abstract][Full Text] [Related]
15. Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy. Jimenez-Pacheco A; Diaz-Hernandez M; Arribas-Blázquez M; Sanz-Rodriguez A; Olivos-Oré LA; Artalejo AR; Alves M; Letavic M; Miras-Portugal MT; Conroy RM; Delanty N; Farrell MA; O'Brien DF; Bhattacharya A; Engel T; Henshall DC J Neurosci; 2016 Jun; 36(22):5920-32. PubMed ID: 27251615 [TBL] [Abstract][Full Text] [Related]
16. 8-Hydroxy-2-(1H-1,2,3-triazol-1-yl)-1,4-naphtoquinone derivatives inhibited P2X7 Receptor-Induced dye uptake into murine Macrophages. Pacheco PAF; Galvão RMS; Faria AFM; Von Ranke NL; Rangel MS; Ribeiro TM; Bello ML; Rodrigues CR; Ferreira VF; da Rocha DR; Faria RX Bioorg Med Chem; 2019 Apr; 27(8):1449-1455. PubMed ID: 30528164 [TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of a P2X7 Receptor-Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates. Ory D; Celen S; Gijsbers R; Van Den Haute C; Postnov A; Koole M; Vandeputte C; Andrés JI; Alcazar J; De Angelis M; Langlois X; Bhattacharya A; Schmidt M; Letavic MA; Vanduffel W; Van Laere K; Verbruggen A; Debyser Z; Bormans G J Nucl Med; 2016 Sep; 57(9):1436-41. PubMed ID: 27199364 [TBL] [Abstract][Full Text] [Related]
18. Purinergic P2X receptors: structural models and analysis of ligand-target interaction. Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R Eur J Med Chem; 2015 Jan; 89():561-80. PubMed ID: 25462266 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. Lavreysen H; Langlois X; Ahnaou A; Drinkenburg W; te Riele P; Biesmans I; Van der Linden I; Peeters L; Megens A; Wintmolders C; Cid JM; Trabanco AA; Andrés JI; Dautzenberg FM; Lütjens R; Macdonald G; Atack JR J Pharmacol Exp Ther; 2013 Sep; 346(3):514-27. PubMed ID: 23766542 [TBL] [Abstract][Full Text] [Related]
20. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor. Hempel C; Nörenberg W; Sobottka H; Urban N; Nicke A; Fischer W; Schaefer M Neuropharmacology; 2013 Dec; 75():365-79. PubMed ID: 23954492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]